Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials.
Reads0
Chats0
TLDR
In this paper, the authors discuss the role and utility of MRI-PDFF as a quantitative and noninvasive imaging-based biomarker in early-phase NASH trials, including potential sample size reduction.About:
This article is published in Hepatology.The article was published on 2018-08-01 and is currently open access. It has received 266 citations till now. The article focuses on the topics: Fatty liver & Nonalcoholic fatty liver disease.read more
Citations
More filters
Journal Article
Review of recent research on hepatitis C therapy for 54th annual meeting of the American association for the study of liver diseases
Journal ArticleDOI
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.
Mohammed Eslam,Philip N. Newsome,Shiv Kumar Sarin,Quentin M. Anstee,Giovanni Targher,Manuel Romero-Gómez,Shira Zelber-Sagi,Vincent Wai-Sun Wong,Jean-François Dufour,Jörn M. Schattenberg,Takumi Kawaguchi,Marco Arrese,Luca Valenti,Gamal Shiha,Claudio Tiribelli,Hannele Yki-Järvinen,Jian-Gao Fan,Henning Grønbæk,Yusuf Yilmaz,Helena Cortez-Pinto,Claudia P. Oliveira,Pierre Bedossa,Leon A. Adams,Ming-Hua Zheng,Yasser Fouad,Wah-Kheong Chan,Nahum Méndez-Sánchez,Sang Hoon Ahn,Laurent Castera,Elisabetta Bugianesi,Vlad Ratziu,Jacob George +31 more
TL;DR: A panel of international experts from 22 countries propose a new definition of metabolic-dysfunction-associated fatty liver disease that is both comprehensive yet simple for the diagnosis of MAFLD and is independent of other liver diseases.
Journal ArticleDOI
Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
TL;DR: The current state of the noninvasive assessment of liver disease in NAFLD is summarized, and an expert synthesis of how these nonin invasive tools could be utilized in clinical practice is provided.
Journal ArticleDOI
Non-alcoholic fatty liver disease
TL;DR: In this paper, a global prevalence of 25% and is a leading cause of cirrhosis and hepatocellular carcinoma, and the leading causes of death in people with NAFLD are cardiovascular disease and extrahepatic malignancy.
Journal ArticleDOI
EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update
Annalisa Berzigotti,Emmanouil Tsochatzis,Jérôme Boursier,Laurent Castera,Nora Cazzagon,Mireen Friedrich-Rust,Salvatore Petta,Maja Thiele +7 more
TL;DR: In this article, the authors provide the latest update to the EASL Clinical Practice Guidelines on the use of non-invasive tests for the evaluation of liver disease severity and prognosis.
References
More filters
Journal ArticleDOI
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
David E. Kleiner,Elizabeth M. Brunt,Mark L. Van Natta,Cynthia Behling,Melissa J. Contos,Oscar W. Cummings,Linda D. Ferrell,Yao Chang Liu,Michael Torbenson,Aynur Unalp-Arida,Matthew M. Yeh,Arthur J. McCullough,Arun J. Sanyal +12 more
TL;DR: A strong scoring system and NAS for NAFLD and NASH with reasonable inter‐rater reproducibility that should be useful for studies of both adults and children with any degree ofNAFLD are presented.
Journal ArticleDOI
Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes
Zobair M. Younossi,Zobair M. Younossi,Aaron B. Koenig,Dinan Abdelatif,Yousef Fazel,Linda Henry,Mark Wymer,Mark Wymer +7 more
TL;DR: As the global epidemic of obesity fuels metabolic conditions, the clinical and economic burden of NAFLD will become enormous, and random‐effects models were used to provide point estimates of prevalence, incidence, mortality and incidence rate ratios.
Journal ArticleDOI
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
Naga Chalasani,Zobair M. Younossi,Joel E. Lavine,Anna Mae Diehl,Elizabeth M. Brunt,Kenneth Cusi,Michael Charlton,Arun J. Sanyal +7 more
TL;DR: This is a practice guideline for clinicians rather than a review article and interested readers can refer to several comprehensive reviews published recently.
Journal Article
Review of recent research on hepatitis C therapy for 54th annual meeting of the American association for the study of liver diseases
Journal ArticleDOI
Sampling variability of liver biopsy in nonalcoholic fatty liver disease.
Vlad Ratziu,Frédéric Charlotte,A. Heurtier,Sophie Gombert,Philippe Giral,Eric Bruckert,André Grimaldi,Frédérique Capron,Thierry Poynard +8 more
TL;DR: Histologic lesions of NASH are unevenly distributed throughout the liver parenchyma; therefore, sampling error of liver biopsy can result in substantial misdiagnosis and staging inaccuracies.